Ametris and the Digital Medicine Society Launch Coalition to Help More Patients Access Immunotherapy Treatments Through Digital Solutions

April 30, 2026

DECODE CRS is a pre-competitive system-wide effort to enable broader patient access to immunotherapies through continuous digital monitoring. By improving understanding of patients’ real-world treatment experience, the initiative aims at developing scalable supportive care approaches that help patients reduce avoidable hospital stays and intensive care use.

PENASCOLA, FL, April 30, 2026 – Ametris, a global digital health solutions provider transforming real-world patient data into validated clinical evidence, and the Digital Medicine Society (DiMe), a global nonprofit organization advancing the safe, effective, equitable, and ethical use of digital technologies, today announced the launch of the DECODE CRS coalition. Alongside principal partner Boehringer Ingelheim and other pharmaceutical organizations across oncology and immunology, the coalition aims to make immunotherapies more widely accessible through continuous digital monitoring.

As immunotherapies move into broader clinical use, care teams are increasingly supporting patients across diverse care settings, including outpatient environments. However, differences in how patient experience is monitored and interpreted in routine care can limit shared learning and slow the development of consistent supportive care approaches. By leveraging continuous data from wearable technologies and standardizing clinical data collection, DECODE CRS seeks to build a more comprehensive, real-world understanding that can enable earlier clinical escalation of adverse events when needed, and support safer outpatient immunotherapy. Ultimately, this leads to more informed clinical decision-making, a reduced burden on healthcare systems, and improved patient outcomes.

The DECODE CRS coalition brings together pharmaceutical sponsors, clinicians, regulators, payers, patients, technology developers, and healthcare systems around a shared goal: to broaden patient access to immunotherapies. Building on DiMe’s foundational work in digital measures related to cytokine release syndrome (CRS), and Ametris’ expertise in continuous sensor-based data analytics, the coalition applies a pre-competitive model to avoid duplication, align approaches, and generate shared evidence. “CRS remains a significant challenge to broader immunotherapy access,” said Mike Akimov MD, PhD, Head of Clinical Development Oncology at Boehringer Ingelheim. “By working collaboratively across the ecosystem, we have an opportunity to generate the shared evidence needed to improve how CRS is detected and managed and enable these treatments to reach more patients.”

“The DECODE CRS coalition is a system-level effort to build shared evidence that no single organization could generate alone,” said Samantha McClenahan, PhD, Associate Program Director, at DiMe. “By learning from patients’ real-world experience in a more consistent and scalable way, this cross-sector collaboration can help translate digital innovation into evidence that supports supportive care, regulatory decision-making, and broader access to immunotherapies.”

The coalition will be organized around two workstreams. The first, launched on April 20, 2026, will define the clinical, commercial, and regulatory requirements for digital CRS monitoring solutions. The second will support a prospective study of at least 150 patients receiving approved CAR-T and TCE immunotherapies to build a robust dataset for early CRS detection. This dataset will facilitate the clearest understanding to date of how CRS across numerous treatments and therapeutic areas onsets, progresses, and is treated under current standards of care. It will also allow for the development of a preliminary wearable-based monitoring algorithm that can be directly compared to these existing standards of care.

“Digital solutions offer a powerful opportunity to better understand how patients experience treatment with immunotherapies in everyday care,” said Christine Guo, Chief Scientific Officer at Ametris. “Through DECODE CRS, we aim to translate continuous monitoring of CRS into shared insights and practical workflows that help reach more patients, including beyond major centers. We are excited to build on the success of our prior DECODE initiatives to improve patient outcomes.”

The DECODE CRS coalition is welcoming additional members interested in advancing digital approaches that support collaborative evidence generation, and broader patient access to innovative immunotherapies. For more information, visit the DECODE CRS project page.